7107-08-6

Basic information

• Product Name: (6-nitrobenzo[1,3]dioxol-5-yl) acetate
• Synonyms: (6-nitrobenzo[1,3]dioxol-5-yl) acetate;NSC 21910
• CAS NO: 7107-08-6
• Molecular Formula: C9H7NO6
• Molecular Weight: 225.16
• Mol File: 7107-08-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 363.4°C at 760 mmHg
• Flash Point: 179.8°C
• Appearance: /
• Density: 1.5g/cm³
• Vapor Pressure: 1.81E-05mmHg at 25°C
• Refractive Index: 1.585
• CAS DataBase Reference: (6-nitrobenzo[1,3]dioxol-5-yl) acetate(CAS DataBase Reference)
• NIST Chemistry Reference: (6-nitrobenzo[1,3]dioxol-5-yl) acetate(7107-08-6)
• EPA Substance Registry System: (6-nitrobenzo[1,3]dioxol-5-yl) acetate(7107-08-6)

Safety Data

• Hazardous Substances Data: 7107-08-6(Hazardous Substances Data)

Usage

Description

(6-nitrobenzo[1,3]dioxol-5-yl) acetate is a chemical compound characterized by a nitrobenzene group attached to a dioxolane ring, which is further linked to an acetate functional group. This unique molecular structure and reactivity make it a promising candidate for various applications in organic synthesis and pharmaceutical research.

Uses

Used in Organic Synthesis:
(6-nitrobenzo[1,3]dioxol-5-yl) acetate is used as a building block for the synthesis of various organic compounds due to the presence of the nitro group in its molecule. This group can be reduced or further reacted to form a wide range of aromatic compounds and heterocycles, making it a versatile precursor in the field of organic chemistry.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (6-nitrobenzo[1,3]dioxol-5-yl) acetate is used as a key intermediate for the development of new drugs or biologically active molecules. The dioxolane ring and acetate functional group provide opportunities for the creation of novel chemical entities with potential therapeutic applications.
Used in the Development of Novel Chemicals:
(6-nitrobenzo[1,3]dioxol-5-yl) acetate is also utilized in the development of novel chemicals, taking advantage of its unique molecular structure and reactivity. (6-nitrobenzo[1,3]dioxol-5-yl) acetate can be a valuable asset in the synthesis of new materials with specific properties, such as improved stability, reactivity, or selectivity, which can be beneficial in various chemical processes and applications.

InChI:InChI=1/C9H7NO6/c1-5(11)16-7-3-9-8(14-4-15-9)2-6(7)10(12)13/h2-3H,4H2,1H3

Upstream product

• 326-58-9 acetic acid benzo[1,3]dioxol-5-yl ester 
• 533-31-3 Sesamol 

Downstream Products

• 6316-25-2 5-benzoyloxy-6-nitro-benzo[1,3]dioxole 
• 7107-10-0 4-hydroxy-5-nitro-1,2,methylenedioxybenzene 

Relevant articles and documents

First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents

The manuscript deals with the design, synthesis and biological evaluation of novel benzoxazinone-based and indole-based compounds as multifunctional neuroprotective agents. These compounds inhibit human adenosine kinase (hAK) and human glycogen synthase kinase 3 beta (hGSK-3β) enzymes. Computational analysis based on a molecular docking approach underlined the potential structural requirements for simultaneously targeting both proteins’ allosteric sites. In silico hints drove the synthesis of appropriately decorated benzoxazinones and indoles (5a-s, and 6a-c) and biochemical analysis revealed their behavior as allosteric inhibitors of hGSK-3β. For both our hit 4 and the best compounds of the series (5c,l and 6b) the potential antioxidant profile was assessed in human neuroblastoma cell lines (IMR 32, undifferentiated and neuronal differentiated), by evaluating the protective effect of selected compounds against H2O2 cytotoxicity and reactive oxygen species (ROS) production. Results showed a strong efficacy of the tested compounds, even at the lower doses, in counteracting the induced oxidative stress (50 μM of H2O2) and in preventing ROS formation. In addition, the tested compounds did not show any cytotoxic effect determined by the LDH release, at the concentration range analyzed (from 0.1 to 50 μM). This study allowed the identification of compound 5l, as the first dual hAK/hGSK-3β inhibitor reported to date. Compound 5l, which behaves as an effective antioxidant, holds promise for the development of new series of potential therapeutic agents for the treatment of neurodegenerative diseases characterized by an innovative pharmacological profile.

NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE

The present invention provides novel methylenedioxy phenolic compounds and their derivatives, methods of making them and methods of using them to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease.